ISCHEMIC HEART DISEASEImaging inflammation and neovascularization in atherosclerosis clinical and translational molecular and structural imaging targetsOsborn, Eric A.a,b; Jaffer, Farouc A.a,cAuthor Information aCardiovascular Research Center, Cardiology Division, Massachusetts General Hospital bCardiology Division, Beth Israel Deaconess Medical Center cCenter for Molecular Imaging Research and Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA Correspondence to Farouc A. Jaffer, MD, PhD, Cardiovascular Research Center, Simches Research Building, 3206 185 Cambridge Street, Boston, MA 02114, USA. Tel: +1 617 724 9353; fax: +1 617 860 3180; e-mail: [email protected] Current Opinion in Cardiology: November 2015 - Volume 30 - Issue 6 - p 671-680 doi: 10.1097/HCO.0000000000000226 Buy Metrics Abstract Purpose of review The purpose of this study is to showcase advances in molecular imaging of atheroma biology in living individuals. Recent findings 18F-fluorodeoxyglucose (FDG) PET/computed tomography (CT) continues to be the predominant molecular imaging approach for clinical applications, particularly in the large arterial beds. Recently, there has been significant progress in imaging of neovascularization and inflammation to delineate high-risk atheroma and to evaluate drug efficacy. In addition, new hardware detection technology and imaging agents are enabling in-vivo imaging of new targets on diverse imaging platforms. Summary In this review, we present recent exciting developments in molecular and structural imaging of atherosclerotic plaque inflammation and neovascularization. Building upon prior studies, these advances develop key technology that will play an important role in propelling new diagnostic and therapeutic strategies identifying high-risk plaque phenotypes and assessing new plaque stabilization therapies in clinical trials. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.